Long-acting disease-modifying therapies do not appear to increase the risk of complications following autologous hematopoietic stem cell transplantation (aHSCT), according to a retrospective study from Sweden (Kvistad et al. J Neurol Neurosurg Psychiatry 2022;93:844-848). Read More
Neurology
Key changes in Canadian MS care during the pandemic
July 7, 2022Pandemic prescribing – what changed?
July 6, 2022Use of disease-modifying therapies for MS changed substantially during the pandemic among clinicians and patients, according to two studies presented at the European Academy of Neurology (EAN) 2022 annual meeting. Read More
EAN 2022 HIGHLIGHTS – THURSDAY, JUNE 30 EDITION
June 30, 2022Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 29 Edition
June 28 Edition
NfL, GFAP elevated post-COVID
Long-term data for anti-CD20 agents
Improved cognitive processing speed with ofatumumab
Cognitive impairment may predict physical disability
B cell kinetics during pregnancy
Clinical tip of the day
Read More
EAN 2022 HIGHLIGHTS – WEDNESDAY, JUNE 29 EDITION
June 29, 2022Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 28 Edition
COVID vaccine response with ofatumumab
Delayed time to wheelchair with siponimod
HSCT – the Swiss experience
Vaccine response to BTK inhibitors
Clinical tip of the day
Read More